Department of Molecular Neurosciences, Center for Brain Research, Medical University Vienna, Spitalgasse 4, 1090, Vienna, Austria.
Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9/163, 1060, Vienna, Austria.
Sci Rep. 2017 Jul 18;7(1):5674. doi: 10.1038/s41598-017-05757-4.
γ-Aminobutyric acid type A (GABA) receptors are pentameric GABA-gated chloride channels that are, in mammalians, drawn from a repertoire of 19 different genes, namely α1-6, β1-3, γ1-3, δ, ε, θ, π and ρ1-3. The existence of this wide variety of subunits as well as their diverse assembly into different subunit compositions result in miscellaneous receptor subtypes. In combination with the large number of known and putative allosteric binding sites, this leads to a highly complex pharmacology. Recently, a novel binding site at extracellular α+/β- interfaces was described as the site of modulatory action of several pyrazoloquinolinones. In this study we report a highly potent ligand from this class of compounds with pronounced β1-selectivity that mainly lacks α-subunit selectivity. It constitutes the most potent β1-selective positive allosteric modulatory ligand with known binding site. In addition, a proof of concept pyrazoloquinolinone ligand lacking the additional high affinity interaction with the benzodiazepine binding site is presented. Ultimately, such ligands can be used as invaluable molecular tools for the detection of β1-containing receptor subtypes and the investigation of their abundance and distribution.
γ-氨基丁酸 A 型 (GABA) 受体是五聚体 GABA 门控氯离子通道,在哺乳动物中,由 19 个不同的基因组成,分别是 α1-6、β1-3、γ1-3、δ、ε、θ、π 和 ρ1-3。这些亚基的多样性以及它们不同的组装成不同的亚基组成导致了多种受体亚型。结合大量已知和假定的变构结合位点,这导致了高度复杂的药理学。最近,在细胞外 α+/β-界面描述了一个新的结合位点,作为几种吡唑并喹啉酮的调节作用位点。在这项研究中,我们报道了一种来自该类化合物的高活性配体,具有显著的β1 选择性,主要缺乏α 亚基选择性。它构成了已知结合位点的最有效β1 选择性正变构调节配体。此外,还提出了一种缺乏与苯二氮䓬结合位点额外高亲和力相互作用的吡唑并喹啉酮配体的概念验证。最终,这些配体可以作为检测含β1 受体亚型的宝贵分子工具,并用于研究其丰度和分布。